Verition Fund Management
ACAD icon

Verition Fund Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Verition Fund Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,749
Closed -$400K – 3463
2025
Q3 		$400K Buy
18,749
+7,244
+63% +$171K ﹤0.01% 3146
2025
Q2 		$248K Sell
11,505
-5,054
-31% -$93.9K ﹤0.01% 3284
2025
Q1 		$275K Sell
16,559
-66,063
-80% -$1.2M ﹤0.01% 2900
2024
Q4 		$1.52M Buy
+82,622
New +$1.33M 0.01% 1747
2024
Q3 		– Sell
-18,829
Closed -$306K – 3146
2024
Q2 		$306K Buy
+18,829
New +$304K ﹤0.01% 2335
2023
Q3 		– Sell
-15,427
Closed -$369K – 2302
2023
Q2 		$369K Buy
+15,427
New +$343K ﹤0.01% 1402
2022
Q3 		– Sell
-11,793
Closed -$166K – 3024
2022
Q2 		$166K Buy
+11,793
New +$220K ﹤0.01% 1989
2021
Q4 		– Sell
-10,036
Closed -$167K – 2507
2021
Q3 		$167K Buy
+10,036
New +$193K ﹤0.01% 1639
2020
Q4 		– Sell
-5,996
Closed -$247K – 1061
2020
Q3 		$247K Sell
5,996
-31,121
-84% -$1.34M ﹤0.01% 860
2020
Q2 		$1.8M Buy
+37,117
New +$1.78M 0.06% 249
2020
Q1 		– Sell
-40,605
Closed -$1.74M – 567
2019
Q4 		$1.74M Buy
40,605
+26,405
+186% +$1.15M 0.03% 293
2019
Q3 		$511K Sell
14,200
-47,174
-77% -$1.43M 0.01% 618
2019
Q2 		$1.64M Buy
+61,374
New +$1.57M 0.05% 284
2018
Q3 		– Sell
-10,695
Closed -$163K – 1217
2018
Q2 		$163K Buy
+10,695
New +$191K 0.01% 1004
2017
Q4 		– Sell
-9,217
Closed -$347K – 846
2017
Q3 		$347K Buy
+9,217
New +$300K 0.03% 782
2017
Q2 		– Sell
-19,639
Closed -$675K – 889
2017
Q1 		$675K Buy
+19,639
New +$693K 0.06% 413

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Verition Fund Management's ACAD Position: Q4 2025 in Review

Verition Fund Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 18,749 shares — an estimated $400K sold.

Verition Fund Management first reported a position in ACAD in Q1 2017 and held it in 16 quarters. The position peaked at $1.8M in Q2 2020. 334 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • Verition Fund Management reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 18,749 Acadia Pharmaceuticals shares in Q4 2025, an estimated $400K.
  • Verition Fund Management first reported a position in Acadia Pharmaceuticals in Q1 2017 and held it in 16 quarters.
  • Verition Fund Management's Acadia Pharmaceuticals position peaked at $1.8M in Q2 2020.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.